Drug Information

Drug General Information
Drug ID
D01QIN
Former ID
DAP000553
Drug Name
Atorvastatin
Synonyms
Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
Drug Type
Small molecular drug
Indication Cardiovascular disease; Hyperlipidemia; Dyslipidemia [ICD10:I00-I99, E78] Approved [551871]
Therapeutic Class
Anticholesteremic Agents
Company
Pfizer Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C33H35FN2O5
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
InChIKey
XUKUURHRXDUEBC-KAYWLYCHSA-N
CAS Number
CAS 134523-00-5
PubChem Compound ID
60823
PubChem Substance ID
9052, 822166, 7884979, 7978735, 8187078, 14910832, 26684326, 26697359, 29215408, 43118161, 49845979, 50037926, 51091801, 53787715, 56311281, 56311722, 56311943, 56311969, 56312802, 56313042, 56313334, 56313578, 56314463, 57314133, 75432172, 85856289, 92714388, 93166494, 103554720, 104178840, 104321734, 104829550, 117367061, 124892211, 126525305, 126624171, 126658151, 126682126, 127315782, 127315783, 127315784, 127315785, 127315786, 127315787, 127315788, 127315789, 127315790, 127315791, 127315792, 127315793
ChEBI ID
ChEBI:39548
SuperDrug ATC ID
C10AA05
SuperDrug CAS ID
cas=134523005
Target and Pathway
Target(s) 3-hydroxy-3-methylglutaryl-coenzyme A reductase Target Info Inhibitor [535246]
BioCyc Pathway Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
Superpathway of cholesterol biosynthesis
Mevalonate pathway
KEGG Pathway Terpenoid backbone biosynthesis
Metabolic pathways
Biosynthesis of antibiotics
AMPK signaling pathway
Bile secretion
NetPath Pathway IL5 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
TSH Signaling Pathway
PANTHER Pathway Cholesterol biosynthesis
PathWhiz Pathway Steroid Biosynthesis
WikiPathways Statin Pathway
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Activation of Gene Expression by SREBP (SREBF)
SREBF and miR33 in cholesterol and lipid homeostasis
Integrated Breast Cancer Pathway
SREBP signalling
Cholesterol Biosynthesis
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535246Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.